Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers

Luisa Anelli 1, Antonella Zagaria 1, Giorgina Specchia 2, Pellegrino Musto 1, and Francesco Albano 1, *

1 Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology and Stem Cell Transplantation Unit, University of Bari “Aldo Moro”, 70100 Bari, Italy; luisa.anelli@uniba.it (L.A.); antonellazagaria@hotmail.com (A.Z.); pellegrino.musto@uniba.it (PM)
2 School of Medicine, University of Bari ‘Aldo Moro’, 70100 Bari, Italy; specchiagiorgina@gmail.com

* Correspondence: francesco.albano@uniba.it; Tel.: +39-(0)80-547-8031; Fax: +39-(0)80-559-3471

Abstract: Micro RNAs (miRNAs) are a class of small non-coding RNAs that have a crucial role in cellular processes such as differentiation, proliferation, migration, and apoptosis. miRNAs may act as oncogenes or tumor suppressors; therefore, they prevent or promote tumorigenesis, and abnormal expression has been reported in many malignancies. The role of miRNA in leukemia pathogenesis is still emerging, but several studies have suggested using miRNA expression profiles as biomarkers for diagnosis, prognosis, and response to therapy in leukemia. In this review, the role of miRNAs most frequently involved in leukemia pathogenesis is discussed, focusing on the class of circulating miRNAs, consisting of cell-free RNA molecules detected in several body fluids. Circulating miRNAs could represent new potential non-invasive diagnostic and prognostic biomarkers of leukemia that are easy to isolate and characterize. The dysregulation of some miRNAs involved in both myeloid and lymphoid leukemia, such as miR-155, miR-29, let-7, and miR-15a/miR-16-1 clusters is discussed, showing their possible employment as therapeutic targets.

Keywords: circulating miRNAs; epigenetic miRNAs; biomarkers; dysregulated expression

1. Introduction

Micro RNAs (miRNAs) are a subset of human non-coding RNA (ncRNA) that plays an essential role in regulating gene expression, RNA maturation, and protein synthesis [1,2]. ncRNAs have long been considered as “junk” elements; they account for about 75–90% of the human genome and are classified in two main groups according to their length: small (<200 nucleotides; miRNAs) and long (>200 nucleotides; IncRNAs) [2,3]. miRNAs are a subset of small single-stranded ncRNAs of about 19–22 nt that play a crucial role in cell growth, development, and differentiation by regulating gene expression [4,5].

Most human miRNAs map in the introns of coding genes; some may overlap with the exons, less frequently in non-coding regions or next to the 3′-UTR sites, and they are often located in the co-transcribed clusters [6–8]. miRNA distribution in the human genome is not random, and some chromosomes such as 1, 2, 19, and X have higher numbers of miRNAs than others [9]. Several miRNAs are located next to fragile chromosomal sites or breakpoints frequently involved in leukemia rearrangements [10,11]. miRNA synthesis starts in the nucleus with the transcription by RNA Polymerase II/III of stem-loop hairpin structures named primary miRNAs (pri-miRNAs) [12]. The endonuclease Drosha processes pri-miRNAs to produce 60–70 nt precursor miRNAs (pre-miRNAs) that are then exported to the cytoplasm and processed further by the ribonuclease Dicer to produce mature miRNA [13]. Most of the mature miRNAs bind to the “seed” region (5–8 nt long) in the 3′UTR of target mRNA molecules, induce silencing complex (miRISC) and act as post-transcriptional regulators causing mRNA degradation or translational repression via deadenylation, decapping, and exonucleolytic processes [14–17].
Moreover, other regions, such as gene promoters, 5′ UTR, or coding regions, may also be linked by miRNAs [18,19]. Up to 2000 miRNA molecules have been identified, regulating about 60% of protein-coding human genes [20,21]. One miRNA can inhibit many different mRNA transcripts, often with similar functions, and control multiple signaling pathways [22]; conversely, one mRNA transcript can be targeted by several miRNAs [23]. miRNA expression is highly tissue-specific, some miRNAs being expressed in a specific cell or tissue type; deregulation of miRNA expression has been associated with several diseases and cancers. Almost 50% of miRNAs are located near or within genes translocated in cancer [24].

By down-regulating the expression of oncogenes or tumor suppressors, miRNAs can prevent or promote tumorigenesis; therefore, they may act as oncogenes (onco-miRs) or tumor suppressors [25]. Abnormal expression of miRNA has been reported in many malignancies, in which tumor suppressors are downregulated and oncogenic miRNAs overexpressed. The roles of miRNA in leukemia pathogenesis are still emerging, and several studies have suggested miRNA expression profiles using as biomarkers for diagnosis, prognosis, and response to therapy in leukemia. These aspects will be discussed in the present review considering their mechanisms of action and the miRNAs most frequently deregulated in myeloid or lymphoid leukemias.

2. Epigenetic miRNAs (epimiRNAs)

MiRNA synthesis may be regulated at the transcriptional or post-transcriptional level by the same mRNA targets they inhibit [26]. The expression of some miRNAs can be silenced by DNA hypermethylation [27], whereas other miRNAs are regulated by histone modifications at their promoter regions [28]. However, some other miRNAs, defined as epigenetic-miRNAs (epi-miRNAs or epi-miRs), can directly or indirectly influence the expression of known epigenetic regulators such as DNA methyltransferases (DNMTs), HDACs, and components of PRC [29,30]. The first identified example of epi-miRNAs was the miR-29 family members (29a, 29b, and 29c); they regulate the expression of DNMT3A and DNMT3B in lung cancer and acute myeloid leukemia (AML). In vitro experiments showed that the exogenous introduction of these miRNAs in lung cancer or AML cell lines led to the reversion of the neoplastic phenotype by inhibiting different DNA methyltransferases and the consequent hypomethylation and reactivation of other target genes [31–33]. Subsequently, other epi-miRNAs such as miR-101, miR-140, and miR-148a/b, targeting histone-lysine N-methyltransferase EZH2, HDAC4, and DNMT3B, respectively, were identified in different cancers [34–36]. miR-193a is another epi-miRNA with a role in AML progression; it is silenced by the AML1/ETO chimeric protein in cases with t(8;21) translocation [37]. miR-193a is, in turn, able to repress epigenetic regulators such as HDAC3, DNMT3A, and its repressor AML1/ETO [38]. Increasing the expression of this epi-miRNA, apoptosis and differentiation are stimulated in leukemic cells due to inhibition of the AML1-ETO and other epigenetic regulators [37]. Another example of epi-miRNA is miR-217, which was found to be downregulated in chronic myeloid leukemia (CML) K562 cells that were resistant to tyrosine kinase inhibitors (TKI); it was shown that by increasing miR-217 expression in these cells, a reduction of DNMT3A and a significantly increased efficacy of TKI were detected [39]. The discovery of epi-miRNA has provided new possibilities for epigenetic-based therapeutic approaches, in which miR-29 family members, shown to be altered in different types of leukemia, are good targets.

3. Circulating miRNAs

Most miRNAs have an intracellular localization, but circulating miRNAs are detected in cell-free body fluids such as serum, blood, urine, and saliva (Figure 1) [40,41]. Nowadays, many researchers are investigating the possibility of exploiting microRNA dysregulated expression profiles in the bloodstream of leukemic patients as a novel liquid biopsy diagnostic tool. Circulating miRNAs are stable molecules, detectable with high sensitivity and specificity, that could be used as new potential non-invasive biomarkers of both solid
and hematologic neoplasms [42,43]. Despite being cell-free RNA molecules, because of
their small length circulating miRNAs are stable in different physical conditions such
as wide ranges of temperature and pH [42]. Circulating miRNAs are most frequently
included in protective micro-structures, named microvesicles or exosomes, secreted into
body fluids [44]. Exosomes are a class of small membrane-derived vesicles, 30–140 nm
in size, that are secreted by almost all cell types and contain different nucleic acids and
proteins that are crucial for intracellular communication [45,46]. It has been hypothesized
that the exosomes intake can cause reduced miRNA presence in cell-free body fluids in
cancer patients by neoplastic cells [47]. On the other hand, increased miRNA levels in the
circulation in cancer patients may be due to miRNA molecules released from neoplastic
infiltrating cells and dying tumor cells. Indeed, circulating miRNAs may also be included
in apoptotic bodies deriving from damaged cells [44]. Although the role of the exosomal
miRNA in the pathogenesis of hematologic malignancies is not yet clear, it has been shown
that exosomes derived from chronic lymphocytic leukemia (CLL) cells have a role in induc-
ting tumor progression [48,49]. CLL cells release more exosomes in plasma than normal
B-cells, and a significant overexpression of several miRNAs (miR-150, miR-155, miR-146a,
and miR-29a) that promote CLL cells survival and growth has been demonstrated [48].
In particular, the expression level of miR-155 in plasma samples of CLL patients seems
to be helpful as a biomarker to identify patients that may not respond satisfactorily to
therapy [50]. A recent study investigated whether serum levels of miRNAs can be used as
a predictive biomarker of CLL. It was found that miR-29a, miR-150-5p, and miR-155-5p
were upregulated in the early stages of CLL, but that these miRNAs were poor predictive
biomarkers of CLL risk [51].

Moreover, it has been shown that exosomes derived from CLL cells are actively taken
by normal stromal cells, and some miRNAs such as miR-202-3p were found to be enriched
in recipient cells, resulting in the downregulation of target genes [52]. Similarly, an in vitro
study showed an increased level of some miRNAs (miR-146a and miR-21) in exosomes de-
derived from multiple myeloma (MM) cell lines inducing proliferation, chemokine synthesis,
and transformation of mesenchymal stem cells co-cultured with MM cells [53,54]. Moreover,
an in vivo study showed that exosomes derived from MM bone marrow (BM) mesenchy-
mal stromal cells could stimulate MM cell growth and disease progression [55]. Overall,
these studies demonstrated an important role of exosomes in mediating miRNAs transfer
between cancer cells and their surrounding microenvironment in B-cell malignancies.

The prognostic value and utility of circulating miRNAs as biomarkers were also
demonstrated in MM. Two miRNAs, let-7b and miR-18a were associated with a poor
outcome when analyzed in exosomes from treated MM patients [56]. Moreover, miR-
let-7c, miR-20a, miR-103a, miR-140, and miR-185a were downregulated, whereas miR-
4505 and miR-4741 were found to be higher in serum from MM patients as compared to
smoldering MM cases, suggesting that exosomal miRNAs can be used as biomarkers for
MM progression [57]. Furthermore, circulating miRNAs can also be used as biomarkers
for drug resistance, since miR-16-5p and miR-15a-5, targeting BCL-2, were found to be
significantly downregulated, whereas miR-20a-5p and miR-17-5p, targeting MYC, were
upregulated in bortezomib-resistant MM patients [58].

Moreover, several circulating miRNAs in plasma or serum of AML patients could be
novel, useful biomarkers, such as miR-92a, that shows a significantly lower expression
in patients as compared to healthy individuals [59,60], the combination of miR-150
and miR-342, that is a potential predictor of relapse [61], or miR-181b-5p, that is significantly
associated with overall survival (OS) [62]. A recent report showed that miR-155 dosage
in serum-derived extracellular vesicles could be a helpful non-invasive biomarker for
different hematologic malignancies such as CLL, AML, myelodysplastic syndrome, and
MM [63].
Figure 1. Schematic representation of miRNA employment as biomarkers in leukemia, based on invasive and non-invasive approaches for expression analysis.

However, several studies revealed different miRNA expression profiles in serum and plasma; therefore, the choice of the sample type is crucial in the use of circulating microRNAs as biomarkers [64]. Moreover, standardization of the experimental protocols to isolate exosomes and quantify circulating miRNAs is needed [65].
4. miRNAs and lncRNAs Interaction

Several data showed that many lncRNAs have multiple miRNA response elements (MRE), that are regions mediating reciprocal interaction; lncRNAs could therefore influence miRNA expression as they can act as sponges in both normal and cancer cells, determining several interactive networks. For example, the interaction between lncRNA ZFAS1 and miR-150 has been demonstrated in silico and functional analyses, with ZFAS1 inducing miR-150 downregulation. It has been demonstrated that the inhibition of ZFAS1 in AML suppresses disease progression by inducing miR-150 overexpression and the downregulation of mRNA targets such as Myb and Sp1 [66]. Moreover, lncRNA HOTAIR1M1 targets and binds the tumor-suppressor miR-193a and modulates c-Kit expression in AML [67]. HOTAIR1M1 also showed an essential role in the pathogenesis of AML cases with the t(15;17) translocation, acting as a microRNA sponge sequestering several miRNAs [68]. Several recent papers reported different miRNA and lncRNA interactions in AML, such as LINC01018 and miR-499a-5p, with LINC01018 acting as a sponge of miR-499a-5p, which in turn targets PDCD4 gene [69]. Both LINC01018-overexpression and miR-499a-5p knockdown suppressed AML cell proliferation and induced apoptosis, whereas miR-499a-5p transfection and silencing of PDCD4 reversed these effects [69]. A further interesting example in AML is represented by the regulatory network of MALAT1/miR-146a/CXCR4. LncRNA MALAT1 and CXCR4 were upregulated, while miR-146a was downregulated in AML patients compared with healthy controls. MALAT1 promotes migration and proliferation of AML cells by sponging miR-146a and stimulating CXCR4 expression [70].

Moreover, lncRNA and miRNA interaction seem to be frequently involved in chemoresistance mechanisms in AML, as for lncRNA-UCA1/miR-125a/hexokinase 2 or HOAX-AS2/miR-520c-3p/S100A4 pathways [71,72]. UCA1 expression was found upregulated following adriamycin (ADR)-based chemotherapy, and UCA1 knockdown enhanced the ADR cytotoxic effect in ADR-resistant AML cells. LncRNA UCA1 directly binds and inhibits miR-125a, positively regulating its target hexokinase 2 (HK2) [71]. On the other hand, lncRNA HOXA-AS2 was significantly upregulated in BM cells from AML cases after ADR-based chemotherapy, and its knockdown inhibited cell proliferation and induced apoptosis. HOXA-AS2 and miR-520c-3p interaction were demonstrated by luciferase reporter assay, and S100A4 was predicted as a downstream target. These data showed that both lncRNAs UCA1 and HOAX-AS2 may represent useful therapeutic targets for overcoming ADR-chemoresistance in AML [72].

Another interesting example is represented by the network between lncRNAs and MYC expression in both myeloid and lymphoid malignancies, which contributes to inhibiting apoptosis, stimulates cell proliferation, induces genomic instability and resistance to therapy [73]. Several autoregulatory loops have been reported in which MYC influences lncRNAs expression and is regulated by lncRNAs. In AML, lncRNA CCAT1 interacts and inhibits miR-155, whose targets are MYC, AP-1, FOS, and c-JUN, which regulate myeloid cell differentiation [74,75]. CCAT1 sponges miR-155 and stimulates MYC expression; interestingly, in previous studies, CCAT1 has been reported to be activated by MYC, suggesting the existence of a MYC/CCAT1/miR-155 feedback loop [75]. Other identified pathways in AML are CCAT1/miR-490-3p/MAPK1/MYC and KCNQ1OT1/miR-326/MYC, in which both lncRNAs CCAT1 and KCNQ1OT1 sponge their target miRNAs and enhance MYC expression [75]. Other examples of lncRNA and miRNA interaction include MEG3/miR-147 and UCA1/miR-16 that have been detected in CML and are considered possible therapeutic targets in blast crisis or imatinib (IM) resistance, respectively [76,77]. Moreover, in lymphoma, the interaction between HOTAIR and miR-148b regulates apoptosis and the cell cycle progression of B cells. miR-148b suppresses the expression of BMI1, which, in turn, activates the MAPK and ERK pathways in B cells [78].

5. miRNAs and CircularRNAs Interaction

CircularRNAs (circRNAs) are a peculiar group of lncRNAs, composed of hundreds to thousands of nucleotides, derived from exonic, intronic (circular intronic RNAs, ciRNAs),
or 5′ and 3′ UTR sequences by back-splicing of precursor mRNAs, that form a closed single-strand RNA transcript loop without a 5′ end cap and 3′ end poly(A) tail [79]. Due to their conformation, circRNAs are resistant to ribonuclease activity and are much more stable, as compared to their linear counterparts, also showing a higher sequence-conservation between species. CircRNAs have been shown to play important roles as miRNA sponges, and regulators of gene splicing and transcription, with some of them able to bind or sequester proteins, or can be translated into functional peptides [80]. As non-coding linear IncRNAs and protein-coding mRNAs, most of circRNAs have MRE regions that can bind miRNAs; therefore, all these RNA molecules compete for limited miRNAs and form a competitive endogenous RNA (ceRNA) regulatory network known as “circRNA-IncRNA-miRNA-mRNA” [81]. The majority of circRNAs are predominantly cytoplasmic and have been reported to work as ceRNAs that act as miRNA sponges. The ceRNA network plays a crucial role in physiological and pathological processes such as solid and hematologic cancers [81]. Moreover, circRNAs are widely distributed in the plasma, urine, saliva, and other human components; therefore, they can be used as promising biomarkers and therapeutic targets [82]. To date, several circRNAs have been identified as diagnostic and prognostic biomarkers in hematological malignancies, such as AML, CLL, CML, and ALL. In AML, three circRNAs have been most frequently reported as upregulated: circDLEU2, circHIPK2, and circPAN3 involved in circDLEU2/miR-496/PPKACB, circHIPK2/miR-124-3p, and circPAN3/miR-153-5p pathways, respectively. CircDLEU2 seems to stimulate AML pathogenesis, circHIPK2 is involved in myeloid cell differentiation and can be considered an acute promyelocytic leukemia-associated biomarker, whereas the oncogenic circRNA circPAN3 has a crucial role in AML drug resistance [83–85]. In CLL, known deregulated pathways are represented by circCBFB/miR-607/FZD3 inducing Wnt/b-catenin signaling, circMT01/miR-337-3p/PML that is downregulated in CLL patients, and circRPL15/miR-146b-3p that inhibits the RAS/RAF1/MEK/ERK pathway [86–88]. In CML, examples of circRNA and miRNA interaction are circTNS3/miR-29b that stimulates leukemic cell proliferation, circHIPK3/miR-24 that is involved in CML progression, and circBA9.3 that upregulates the expression of BCR-ABL1 and reduces TKI sensitivity [84,89]. In ALL, several reports describe the upregulation of circPVT1 in BM samples of patients as compared to healthy individuals; it has been demonstrated that the circPVT1 knocking down inhibits the expression of MYC and the anti-apoptotic protein BCL-2, showing that circPVT1 could be used as a promising new therapeutic target [90].

6. miRNAs Expression Profile in Leukemia

MiRNA expression is tissue-specific, as different miRNAs are expressed in a specific cell or tissue type; miRNAs play a crucial role in regulating gene expression during normal hematopoiesis, acting on the self-renewal capacity of hematopoietic stem cell (HSC) and the differentiation of lineage-restricted progenitors [91,92]. Thirty-three miRNAs were identified as specifically expressed in CD34+ hematopoietic stem-progenitor cells (HSPCs) [93]. Some miRNAs such as miRNA-17, -24, 146, -155, -128, and -181, were found to be expressed in early hematopoietic cells—whereas other miRNAs, such as miRNA155, were able to control specific processes, as myelopoiesis and erythropoiesis [93], or as miR-34a and miR-17-92 clusters that have an essential role in the pro- to pre-B-cell differentiation [94]. miR-181 cluster also plays a critical role in the differentiation of hematopoietic cells as T, B, and natural killer cells or megakaryocytes [95].

Deregulation of miRNA expression has been associated with several diseases and cancers, and specific miRNA expression profiles have been reported in several hematologic neoplasms [96,97]. Microarray technologies, next-generation sequencing (NGS), and quantitative real-time PCR (qRT-PCR) are the most valuable methodologies for identifying reproducible dysregulated expression profiles in specific leukemia types (Figure 1). Unlike microarray analysis, NGS by miRNA-Seq shows high sensitivity in discovering new miRNAs and detecting whole-genome miRNA transcripts (miRNoma) with no need for previous selection. Therefore, the recent development of NGS technologies has made it
possible to identify an increasing number of miRNAs involved in leukemogenesis. Several of these miRNAs may potentially be used as prognostic biomarkers, either as single miRNAs or as miRNA expression profiles.

The first evidence of the involvement of miRNAs in leukemogenesis was reported in a study of CLL aimed at characterizing a 30 Kb deletion on 13q14; the study did not identify any protein-coding genes, but a cluster of two miRNAs, miR-15a and miR-16-1, was found to be deleted or down-regulated in most of the CLL cases examined [98]. Moreover, these miRNAs have also been shown to be frequently deregulated in other solid and hematological cancer types [99–101], and can modulate cell cycle progression and induce apoptosis by targeting pivotal genes such as BCL2, MCL1, CCND1, or WNT3A [102–104].

6.1. Acute Myeloid Leukemia

Different studies reported specific miRNA expression profiles that distinguish between AML and acute lymphoblastic leukemia (ALL), some miRNAs being reported in different studies, such as miR-23a, miR-27a/b, miR-128a, miR-128b, miR-221, miR-222, miR-223, and let-7b [105,106]. In a study by Mi et al., four miRNAs were sufficient to distinguish between AML and ALL with an accuracy of greater than 95%, as let-7b/miR-223 being significantly upregulated and miR-128a/miR-128b downregulated in AML comparing to ALL [105]. Together, the above work showed that these identified miRNAs could be new potential markers for ALL and AML classification and diagnosis [62].

One of the miRNAs most frequently involved in AML pathogenesis is miR-155 (Figure 2), which is also commonly overexpressed in B-cell neoplasms, where it is considered an oncogenic driver of B-cell lymphoma [107]. This miRNA shows a contrasting dose-dependent function as onco-miRNA or tumor suppressor according to the expression levels. In short, a high level of expression is correlated with the antitumor effect and inhibition of AML cell proliferation. In contrast, an intermediate-low level of expression induces oncogenesis [108] and has been associated with poor prognosis in AML irrespective of specific cytogenetic or molecular aberrations [108].

Figure 2. Most frequent miRNAs showing dysregulated expression in myeloid or lymphoid leukemia.
Several studies have identified specific miRNA signatures in different AML subgroups defined by the classification of myeloid neoplasms [109] (Table 1), and a correlation was detected with cytogenetics alterations [110–112], prognosis, and clinical characteristics [65].

Table 1. miRNAs most frequently involved in acute leukemia pathogenesis.

| AML miRNAs | Expression Data | References |
|-------------|-----------------|------------|
| t(15;17)(q24;q21) PML-RARA | miR-127, miR-154, miR-154*, miR-299, miR-323, miR-368, miR-370, miR-382, miR-134, miR-376a, miR-127, miR-299-5p, miR-323, miR-224 | Upregulation of miRNAs mapping in the 14q32 imprinted region [110–112] |
| t(8;21)(q22;q22.1) RUNX1-RUNXIT1 | miR-126, miR-146a, miR-133a, let-7b, let-7c | Overexpression of miR-126 and miR-146a; downregulation of miR-133a let-7b and let-7c [111–113] |
| inv(16)(p13.1q22) CBFβ-MYH11 | miR-99a, miR-100, miR-224, miR-126 | miRNA signature sometimes overlapping with t(8;21) AML [110–112] |
| FLT3-ITD | miR-155, miR-10a, miR-10b | Upregulation [111,114] |
| Mutated NPM1 | miR-10a and b, let-7, miR-29, miR-15a/16-1, miR-17-18a-19a-20a, miR-204 and miR-128a | Upregulation of miR-10a and b, let-7, miR-29, miR-15a/16-1, and miR-17-18a-19a-20a; downregulation of miR-204 and miR-128a [114–116] |
| MLL rearranged | miR-34b, miR-15a, let-7 family, miR-196, miR-10a, miR-331, and miR-340, miR-17-92, miR-126, -126*, -224, -368, -382, 17-5p, and -20a | Downregulation of miR-34b, miR-15a, let-7, and miR-196; upregulation of miR-17-92, miR-126, -126*, -224, -368, -382, 17-5p, and -20a [110,112,117] |
| Mutated IDH2 | miR-125b, miR-1, miR-133, miR-194-1, miR-526, miR-520a-3p, miR-548b | Upregulation of miR-125b, miR-1 and miR-133; downregulation of miR-194-1, miR-526, miR-520a-3p, and miR-548b [118] |
| Mutated RUNX1 | miR-223, let-7, miR-211, miR-220, miR-595 | Downregulation of miR-223 and let-7; upregulation of miR-211, miR-220, and miR-595 [119] |
| Normal karyotype | miR-181a/b, miR-124, miR-128-1, miR-194, miR-219-5p, miR-220a, miR-320 | Upregulation [120] |
| ALL | miR-128b, miR-708, miR-125b, miR-203 | Overexpression of miR-125b, miR-203 |
| hyperdiploid karyotype | miR-222, miR-223, miR-374, miR-660, miR-98 and miR-511 | Upregulation [122] |
| hyperdiploid karyotype | miR-126, miR-146a, miR-511, miR-545, miR-365, miR-24, miR-30d, miR-193, miR-181, miR-708 | Downregulation of miR-126, miR-146a, miR-511, miR-545, miR-365, miR-24, miR-30d, miR-193; upregulation of miR-181, miR-708 [123,127] |
| T-ALL | miR-17-92, miR-708, miR-196b, miR-128, miR-181, miR-29, miR-150, miR-99a and miR-708 | Overexpression of miR-17-92, miR-708, miR-196b, miR-128, miR-181; Downregulation of miR-29 [128–130] |
In AML with the t(15;17) translocation, the upregulation of miRNAs located in the 14q32 imprinted domain (miR-127, miR-154, miR-154*, miR-299, miR-323, miR-368, and miR-370) was reported in a first study [110], whereas a set of partially overlapping strongly upregulated microRNAs (miR-382, miR-134, miR-376a, miR-127, miR-299-5p, and miR-323) was described by Jongen-Lavrencic et al. [111]. In another study, the overexpression of miR-224, miR-368, and miR-382 was detected [112].

AML with (8;21) showed high miR-126/126* [112] and miR-146a expression with decreased miR-133a [110]; other evidence showed a set of down-regulated miRNAs, including two members of a known tumor suppressor microRNA family, let-7b and let-7c [111], that was previously found to be involved in other cancers [113].

In AML with inv(16), a high level of miR-99a, miR-100, and miR-224 expression or of miR-126/126* was observed by different investigators [110,112]. Overall, AML with inv(16) showed a miRNA signature that sometimes overlapped with t(8;21) AML; this is not surprising as both these AML subtypes belong to the CBF group [111].

In AML with FLT3-internal tandem duplication (FLT3-ITD), miR-155, miR-10a, and miR-10b were found to be upregulated [111,114].

In AML with NPM1 mutations, a specific miRNA-based expression signature was revealed with upregulation of miR-10a and b, members of the let-7 and miR-29 families, miR-15a/16-1 and miR-17-18a-19a-20a clusters, and downregulation of miR-204 and miR-128a, predicted to target HOX genes known to be upregulated in NPM1 mutated AML [114,115]. A further study was based on an integrative approach based on both microRNA and gene expression profiles. Several interesting microRNA-target mRNA interactions, such as IRF2-miR-20a, KIT-miR-20a, and MN1-miR-15a, were identified. This study also showed a deregulated expression of tumor suppressor microRNAs, such as miR-29a and miR-30c, that seem to be involved in sensitivity to therapy [116].

In AML with balanced 11q23 translocations and KMT2A (MLL) rearrangements, the downregulation of several tumor suppressor miRNAs such as miR-34b, miR-15a, the let-7 family, and miR-196, targeting several known target genes such as CDK4 and CCNE2, BCL2, RAS, and HOX genes was reported; other evidence showed that AML with the MLL rearrangement were characterized by the loss of miR-10a, miR-331, and miR-340 expression [110]. Other authors revealed the overexpression of miRNAs from polycistronic cluster miR-17-92, and a minimal class predictor with only seven miRNAs (miR-126, -126*, -224, -368, -382, 17-5p, and -20a) was identified [112]. Leukemic cells with higher expression levels of miR-17-92 showed arrested differentiation and increased proliferation in concomitance with reduced expression of p21, a downstream target of polycistronic miR-17-92 [117].

In AML with IDH2 mutations, a specific signature for R172 IDH2-AML was identified with the upregulation of miR-125b, which targets the TP53 gene and inhibits myeloid differentiation, miR-1 and miR-133, involved in embryonic stem-cell differentiation, and downregulation of miR-194-1, miR-526, miR-520a-3p, and miR-548b, not previously associated with normal hematopoiesis or AML [118].

In AML with RUNX1 mutations, miR-223 and two members of the let-7 tumor suppressor family were downregulated, whereas three miRNAs with an unknown role in leukemogenesis, miR-211, miR-220, and miR-595, were found to be upregulated [119].

MiRNA expression analysis performed on normal karyotype AML (CN-AML) revealed a prognostic relevant miRNA signature, as the upregulation of miR-181a/b and miR-124, miR-128-1, miR-194, miR-219-5p, miR-220a, and miR-320 was associated with a low or increased risk of failure to achieve complete remission (CR), of relapse or death, respectively [120]. Some miR-181 putative targets were genes involved in innate immunity, encoding interleukins, caspases, and Toll-like receptors [120].

6.2. Acute Lymphoblastic Leukemia

miRNAs deregulation is a common event in B- and T-cell malignancies in which they act as either oncomiRs or tumor suppressors [94,122,131]. A different miRNA expression
profile, mostly based on miR-92a, miR-100, miR-125a-5p, miR-128a, miR-181b, miR-196b, and let-7e was revealed when comparing B-ALL lymphoblasts to normal CD34+ cells [132]. In ALL, the most frequently altered miRNAs are miR-181 cluster that is reported as up-regulated by several studies and is considered a crucial oncomiR in childhood ALL [122]; miR-155, that induces pre-B cells clonal expansion and is overexpressed in different pediatric ALL subtypes [107]; miR-128b, that allows differentiation with AML cases and is downregulated in ALL with the MLL-AF4 translocation [105,121]. In MLL-rearranged ALL, miR-708 and let-7b downregulation are also frequently detected, probably because of DNA hypermethylation caused by the MLL fusion protein itself. Other frequently deregulated miRNAs in ALL are miR-100, miR-125b, miR-99a, miR-126, and let-7c that are overexpressed in ETV6-RUNXI patients [122,123], whereas miR-181a was found as markedly downregulated in this subtype of ALL [124,125] (Table 1). In BCR-ABL1 positive ALL cases, miR-125b expression level is downregulated at diagnosis, but significantly overexpressed after about a month. Moreover, miR-203 is silenced through epigenetic mechanisms [126]; it has been shown that by enhancing miR-203 expression, BCR-ABL1 transcript level is reduced, cell proliferation is inhibited, and resistance to TKI can be overcome [133]. Regarding ALL with hyperdiploid karyotype, miR-222, miR-223, miR-374, miR-660, miR-98, and miR-511 were found upregulated, probably as a consequence of their mapping location in chromosomes X and 10 that are frequently present as extra copies [122].

Moreover, miRNAs expression profile data allowed the discrimination between T and B-lineage ALL based on several miRNAs such as miR-148, miR-151, and miR-424 [134]. In T-ALL, the oncogenic miR-17-92 cluster was found to be overexpressed as a consequence of the t(13;14)(q32;q11) translocation, which juxtaposed the miR-17-92 locus next to the enhancer of the T-cell receptor alpha/delta locus [135] (Table 1). miR-708 was found upregulated when comparing T-ALL with healthy individuals and downregulated when comparing T-ALL with different leukemia subtypes [122]; miR-708 downregulation is a poor prognostic factor of T-ALL, as it induces an increased expression of CD47 and promotes the evasion of leukemic cells from macrophage-mediated phagocytosis [136]. Another miRNA frequently dysregulated in T-ALL is miR-196b that is probably upregulated as a consequence of its mapping position between HOXA9 and HOXA10 genes that are often overexpressed [137]. Other miRNAs found to be dysregulated in T-ALL were miR-128, the oncogenic cluster miR-181, and the tumor-suppressive miR-29 [128–130]. Moreover, in childhood, ALL three main miRNAs were frequently reported as prognostic markers: miR-150, miR-99a, and miR-708. Low levels of miR-150 expression were associated with poor prognosis as correlating with relapse, high-risk and high WBCs at diagnosis; the association of miR-150 downregulation and poor prognosis was also revealed in other hematologic malignancies as AML, CLL, and different lymphoma subtypes [94]. Regarding miR-99, different studies revealed that upregulation and downregulation were correlated with favorable and poor prognosis, respectively [138,139]. Finally, miR-708 upregulation was associated with a good prognosis, as lower relapse risk, low WBC count, and better overall survival were detected in ALL cases; on the contrary, miR-708 downregulation was revealed in poor prognosis subtypes as T-ALL and cases with MLL gene rearrangement [122,139]. Finally, in ALL with TCF3-PBX1 fusion, the deregulation of several miRNAs was also revealed (Table 1) [123,127].

6.3. Chronic Myeloid Leukemia

Regarding the involvement of miRNAs in chronic myeloid leukemia (CML) pathogenesis, recently it has been shown that miR-155 was highly up-regulated in CD34+ CML cells and allowed to evade growth-inhibitory effects of the TGF-β1 and bone morphogenetic protein (BMP) signaling; these findings provided new perspectives for miR-155 as a potential target for CML therapy [140]. Moreover, recent data revealed that miR-300 is a tumor suppressor miRNA inducing quiescence in CML leukemic stem cells (LSCs) [141], and that miR-126-3p influences both quiescence and self-renewal of CML LSCs [142] (Table 2). Another recent study showed a global decrease in microRNA levels in LSC-enriched
CD34^+CD38^−CD26^+ and HSC from CML-CP patients compared to those from healthy donors HSC [143]. Previous findings showed that microRNAs have also been implicated in CML progression, response to treatment, or TKI resistance [144–150]. A study by Edurne San José-Enériz et al. identified a group of 19 miRNAs that may predict clinical resistance to IM in patients with newly diagnosed CML [151]. Another study revealed that miR-30 induces the degradation of BCR/ABL1 mRNAs by binding directly to their 3′UTR, which was downregulated in CML patients less responsive to IM [152]. Lower expression levels of several different miRNAs such as miR-26a, miR-29c, miR-130b, miR-146a, miR-142-5p, and miR-365a-3p were identified in the peripheral blood or BM samples of CML patients who failed to respond to TKI treatment [153–155]. Another miRNA, miR-153-3p, was identified as downregulated in IM-resistant CML cells, and its upregulation significantly increased drug sensitivity and decreased the IM-resistant CML cells’ survival [156]. The downregulation of miR-153-3p, which directly targets B-cell lymphoma-2-mediated (Bcl-2), reduces sensitivity to IM and attenuates IM-induced apoptosis in CML. These data showed that the employment of miR-153-3p-mimic transfection combined with IM therapy might represent a promising strategy for patients with low TKI sensitivity [156]. A global transcriptome profile analysis performed on CML stem cells at diagnosis identified miR-185 as one of the most deregulated miRNAs, with a significant reduction in TKI non-responders compared with responders. The miR-185 restored expression impaired survival of TKI resistant cells, therefore miRNA targeting in combination with conventional TKI therapy may represent an efficient strategy for overcoming drug resistance in CML [156].

### Table 2. miRNAs most frequently involved in chronic leukemia pathogenesis.

| CML          | miRNAs                          | Expression Data                                                                 | References |
|--------------|---------------------------------|---------------------------------------------------------------------------------|------------|
| pathogenesis | miR-155, miR-300, miR-126-3p    | Upregulation of miR-155, miR-300; Downregulation of miR-126-3p               | [140–142]  |
| TKI resistance | miR-30, miR-26a, miR-29c, miR-130b, miR-146a, miR-142-5p, miR-365a-3p, miR-153-3p, miR-185 | Downregulation                                                                   | [152–154,156] |
| TKI discontinuation | miR-148b and miR-215 | Downregulation                                                                 | [152–154,156,157] |
| CLL          | miRNAs                          | Expression Data                                                                 | References |
| 13q deletion | miR-15a/miR-16-1 cluster, miR-34a/miR-34b/miR-34c cluster | Downregulation of miR-15 and miR-16; upregulation of miR-34 cluster              | [98,158–160] |
| Trisomy 12   | miR-181a                        | Upregulation                                                                    | [159]      |
| 17p deletion | miR-15a, miR-21, miR-34a, miR-155, and miR-181b | Upregulation of miR-21, miR-34a, miR-155, miR-181b      | [161]      |
| 11q deletion | miR-34b/miR-34c cluster         | Downregulation                                                                  | [160]      |

In contrast, another recent investigation did not find any significant differences in miRNA expression patterns between TKI responder and non-responder patients [162]. Different studies analyzing miRNA expression profiles at CML diagnosis and in cases showing resistance considered only a small series of CML cases and produced contrasting results. More extensive analyses are therefore needed to verify whether the aforementioned miRNAs may be used to discriminate between the responders and non-responders among CML patients as well as the predictive biomarkers for TKI resistance. The miRNA involvement has also been investigated in CML to identify possible biomarkers for TKI discontinuation; two miRNAs, miR-148b and miR-215, showed downregulated expression in CML cases with successful IM discontinuation, suggesting that these miRNAs may contribute to immune surveillance in CML patients showing safe TKI discontinuation [157,163].
6.4. Chronic Lymphocytic Leukemia

MiRNA transcription alterations have been shown in the tumor microenvironment of B-cell malignancies. miRNAs are involved in the regulation of B lymphocyte development and can be altered in different B-cell malignancies. Several studies showed that miRNAs act on various targets playing critical roles in the CLL pathogenesis, such as BCL2, C-FOS, C-MYC, TP53, TCL1, and STAT3. Both intracellular and exosomes miRNAs induce the B cells and B cell antigen receptor (BCR) activation, stimulate CLL cell progression, and could therefore be used as potential diagnostic and therapeutic biomarkers for CLL. To date, several differentially expressed miRNAs have been identified in different studies on CLL based on miRNAs transcriptional profiling (Table 2). In the pilot study by Calin et al., a 13 miRNA signature was identified in CLL patients with high ZAP70 expression and the unmutated status of the variable region of the immunoglobulin heavy chain (IGHV) [158]. Moreover, other studies defined specific miRNA signatures in CLL with karyotype alterations such as del(13q), trisomy 12, del(17p), and del(11q) [159,161] (Table 2). In about two-thirds of CLL cases, B-cell proliferation is stimulated by miR-15a and miR-16-1 downregulation as a consequence of 13q14 deletion; an inverse correlation between miR-15a/16-1 and the antiapoptotic gene BCL2 expression has been observed, while CLL cell lines with miR-15a/16-1 downregulation showed an increased BCL2 expression and resistance to apoptosis. Furthermore, low miR-15a-5p and miR-16-5p levels induce the upregulation of another target, TP53, that activates the expression of miR-34b-3p and miR-34c-5p and causes the reduction of ZAP-70 levels, leading to an indolent B-CLL phenotype [160]. Several miRNAs such as miR-181, miR-30d, and let-7a were differentially expressed between CLL lymphocytes and CD19+ normal cells [164], whereas another study revealed a reduced expression of miR-125b in both aggressive and indolent CLL [165]. Other miRNAs frequently involved in CLL and other B-cell malignancies are miR-150, miR-155, and the miR-17-92 cluster; they regulate the expression of crucial transcription factors involved in normal or malignant B-cells development [50,166,167]. miR-150 is considered a lymphopoietic-specific miRNA, as its overexpression inhibits the pro-B to pre-B transition, probably by targeting forkhead box P1 (FOXP1) and GRB2-associated binding protein 1 (GAB1), an important transcription factor involved in B-cell differentiation [168–170]. miR-155 was found to be overexpressed in both cells and plasma from CLL cases and resulted to be associated with poor prognosis and disease progression [50]. Therefore, both miR-155 and miR-150 interfere with B-cells differentiation and are involved in CLL pathogenesis. A recent study investigated a possible correlation between the miR-155/miR-150 network and clinical parameters in CLL patients, revealing its association with overall survival and CLL progression [171]. MiR-17/92 is another oncogenic miRNA with a crucial role in CLL pathogenesis and progression, being frequently upregulated and targeting different transcripts as the proapoptotic BCL2L11 and the tumor suppressor PTEN [172]. Moreover, miR-29 was found upregulated in CLL cases compared to healthy individuals suggesting that it can act as an additional oncomiR; its expression was correlated to that of TCL1, a known oncogene with a crucial role in aggressive CLL cases. TCL1 induces AKT activation and inhibits DNA methyltransferases Dnmt3A and Dnmt3B, reducing DNA methylation in CLL cells [173,174]. MiR-29 family deregulation has been specially revealed in exosomes from plasma of CLL patients, as mentioned above [51], and could therefore be employed as a useful biomarker for CLL diagnosis and progression. However, a recent study showed that all miR-29 family members (miR-29a, miR-29b, and miR-29c) were consistently downregulated in the CLL microenvironment as a consequence of BCR activation and seemed to correlate with a significantly shorter overall survival of CLL patients. Tumor-Necrosis Factor Receptor-Associated Factor 4 (TRAF4) has been identified as a novel direct target of miR-29s, and higher TRAF4 levels result in downstream NFκB signaling activation [175]. Finally, some evidence showed that miRNAs could be employed as suitable biomarkers for assessing response to treatment in CLL patients. It has been shown that the treatment with “BCR inhibitor” ibrutinib induces the downregulation of several miRNAs involved in B cell activation, as miR-22, miR-34a, miR-146b, and miR-181b,
whereas the expression of several target genes including ARID1B, ATM, HDAC1, CYLD, FOXP1, IBTK, ARID2, PTEN, and SMAD4 is activated [176]. The therapy with ibrutinib or idelalisib also seemed to disrupt TRAF4 activation induced by miR-29 deregulation [175].

7. miRNAs as Therapeutic Targets

miRNAs play a crucial role in regulating leukemic stem cells and the pathogenesis of hematological malignancies. Some evidence showed the crucial role of miRNAs as regulators of gene expression, biomarkers for diagnosis, prognosis, and progression, as well as molecules with the potential therapeutic application. Nowadays, miRNAs are considered promising therapeutic targets in leukemia because their silencing or inhibition does not interfere with normal HSCs function [177]. The modulation of oncogenic or tumor-suppressive miRNAs may, therefore, allow the development of novel therapeutic strategies. Two commonly investigated therapeutic approaches that allow easy modulation of miRNA levels are miRNA mimics and anti-miRNAs or miRNA-antagomiRs. miRNA mimics are small RNAs molecules that resemble miRNA precursors and can regulate the expression of target proteins; they are delivered to cells by synthetic vectors that avoid degradation and stimulate cellular uptake [178]. Anti-miRNAs are synthetic molecules complementary to endogenous miRNA that can interfere and inactivate target oncogenic miRNAs [179]. In AML, overexpression of the tumor suppressor miR-29b in blast cells was achieved using a nanoparticle-based delivery system and induced the inhibition of leukemic cell proliferation [180]. As for MM, administering miR-15a/16-1 to in vivo xenograft models showed a good efficacy, while the employment of miR-34 synthetic mimics induced apoptosis and the inhibition of MM cells in vitro [181]. MiR-16-5p mimics or lentiviral vectors were also employed in different CLL studies performed on mouse models to restore miR-15a-5p and miR-16-5p expression levels, showing B-cell cycle arrest, decreased cell viability, or induction of apoptosis [182,183]. Moreover, an in vitro synergetic action of miR-16-5p mimics and different chemotherapeutic agents was observed in the induction of apoptosis [182]. The use of lentiviral vectors for the in vivo restoration of miR-15a-5p and miR-16-5p seemed to produce low systemic toxicity and few off-target effects [183]. Another example of miRNA therapy in CLL is represented by miR-18a-5p and miR-18b-5p mimics that induce a significant increase in apoptosis when transfected in leukemic B cells from patients with wild type TP53 and reduce leukemic cell expansion by inhibiting TCL1A, AKT, and phosphorylated ERK1 and ERK2 [184]. An example of a miRNA inhibitor currently in phase 1 clinical trial is MRG-106, a miR-155 inhibitor, now being tested in CLL, diffuse large B-cell lymphoma (DLBCL), and adult T-cell leukemia (NCT02580552). Another anti-miRNA is represented by antagomiR-17-5p that has been in vitro administrated to MEC-1 cells, significantly reducing miR-17-5p expression levels and cell proliferation and showed efficacy in tumor growth inhibition when injected in immunodeficient mice [185]. Interestingly, oncogenic miRNAs such as miR-22, miR-34a, miR-146b, and miR-181b were shown to be significantly decreased in response to therapy with ibrutinib in CLL patients. Knockdown of endogenous miR-34a and miR146b by anti-miRs strategy stimulated tumor suppressors transcription and inhibition of cell proliferation, confirming that these miRNAs target a subset of the tumor suppressor transcripts that were upregulated in response to ibrutinib [176]. As for the in vivo delivery of miRNA mimics and antagomiRs, besides lentiviral systems, antibody-based strategies have also been proposed by conjugating the selected miRNA with antibodies specific for characteristic markers of leukemic cells; these kinds of “vehicles” have been addressed to CD38 and ROR1 antigens expressed on the surface of leukemic B-cells [186,187]. A novel system based on lipid nanoparticles conjugated with an anti-CD38 monoclonal antibody has shown to be highly efficient in transferring miRNAs into leukemic cells, with miR-26a being the most effective in stimulating cell apoptosis [187]. The targeted delivery of miR-29b to ROR1-expressing CLL cells in vivo resulted in enhanced B-cells survival and reduced cell cycle deregulation [186].
However, miRNAs-based therapeutic approaches should be considered cautiously, accurately selecting the miRNAs to target, as some miRNAs can be oncogenic or tumor-suppressive in different conditions. For example, miR-125b affects tumor suppressors in many solid tumors and is an oncomiR in hematologic malignancies [188,189]. Moreover, the mechanism of miRNAs regulation and function has not yet been completely clarified; therefore, the development of miRNA-based treatment strategies should be carefully evaluated to guarantee the safe use of miRNAs therapy in the clinic. In conclusion, more efforts are required to improve miRNA-based therapy specificity and test their efficacy in combination with conventional approaches, avoiding toxicities and off-target effects.

8. Conclusions

Increasing evidence shows that miRNAs have a role as potential biomarkers in leukemia, allowing a better subtype classification, prognostic stratification, and predicting the response to treatment. An ideal biomarker should have a specific expression in patients compared to normal controls, should allow early diagnosis and minimal residual disease monitoring during the follow-up, with a possible non-invasive, simple and accurate detection method. About this, miRNAs can be extracted and analyzed from peripheral blood or bone marrow cells of leukemia patients, while circulating miRNAs can be examined by non-invasive methods based on liquid biopsy analysis and usually show expression profiles overlapping with neoplastic cells (Figure 1). To date, a large number of studies have identified different, but not always overlapping miRNAs as putative biomarkers in the same leukemia subtype, often producing contrasting data. Several miRNAs are frequently dysregulated in leukemia, such as the miR-29, let-7, and miR-15a/miR-16-1 clusters (Figure 2). Among the most frequently altered miRNAs, increasing studies show that miR-155 is involved in the pathogenesis of different myeloid and lymphoid leukemia and may be a useful putative biomarker for liquid biopsies analysis.

Author Contributions: Conceptualization, F.A.; investigation, literature data curation and writing—original draft preparation, L.A. and A.Z.; writing—review and editing, F.A. and G.S.; supervision, P.M. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Associazione Italiana contro le Leucemie (AIL)-BARI.

Acknowledgments: The authors would like to thank. MVC Pragnell, B.A., for language revision of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Morris, K.V.; Mattick, J.S. The rise of regulatory RNA. Nat. Rev. Genet. 2014, 15, 423–437. [CrossRef] [PubMed]
2. Palazzo, A.F.; Lee, E.S. Non-coding RNA: What is functional and what is junk? Front. Genet. 2015, 5. [CrossRef] [PubMed]
3. Collins, L.J.; Penny, D. The RNA infrastructure: Dark matter of the eukaryotic cell? Trends Genet. 2009, 25, 120–128. [CrossRef]
4. Bartel, D.P. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell 2004, 116, 281–297. [CrossRef]
5. Liu, M.; Zhou, K.; Cao, Y. MicroRNA-944 affects cell growth by targeting EPHA7 in non-small cell lung cancer. Int. J. Mol. Sci. 2016, 17, 1493. [CrossRef]
6. Rodriguez, A.; Griffiths-Jones, S.; Ashurst, J.L.; Bradley, A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004, 14, 1902–1910. [CrossRef]
7. Altuvia, Y.; Landgraf, P.; Lithwick, G.; Elefant, N.; Pfeffer, S.; Aravin, A.; Brownstein, M.J.; Tuschi, T.; Margalit, H. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 2005, 33, 2697–2706. [CrossRef]
8. Albano, F.; Anelli, L.; Zagaria, A.; Coccaro, N.; Casieri, P.; Minervini, A.; Specchia, G. SETBP1 and mir-4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia. J. Hematol. Oncol. 2012, 5, 1–4. [CrossRef]
9. Grimwood, J.; Gordon, L.A.; Olsen, A.; Terry, A.; Schmutz, J.; Lamerdin, J.; Hellsten, U.; Goodstein, D.; Couronne, O.; Tran-Gyamil, M.; et al. The DNA sequence and biology of human chromosome 19. Nature 2004, 428, 529–535. [CrossRef]
10. Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 2004, 101, 2999–3004. [CrossRef] [PubMed]
11. Starczynowski, D.T.; Morin, R.; McPherson, A.; Lam, J.; Chari, R.; Wegryn, J.; Kuchenbauer, F.; Hirst, M.; Tohyama, K.; Humphries, R.K.; et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. *Blood* **2011**, *117*, 595–607. [CrossRef]

12. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. *Nat. Rev. Mol. Cell Biol.* **2014**, *15*, 509–524. [CrossRef]

13. Okada, C.; Yamashita, E.; Lee, S.J.; Shibata, S.; Katahira, J.; Nakagawa, A.; Yoneda, Y.; Tsukihara, T. A high-Resolution structure of the pre-microRNA nuclear export machinery. *Science* **2009**, *326*, 1275–1279. [CrossRef]

14. Tan, L.; Yu, J.T.; Tan, L. Causes and Consequences of MicroRNA Dysregulation in Neurodegenerative Diseases. *Mol. Neurobiol.* **2015**, *51*, 1249–1262. [CrossRef] [PubMed]

15. Pfaff, J.; Meister, G. Argonaute and GW182 proteins: An effective alliance in gene silencing. *Biochem. Soc. Trans.* **2013**, *41*, 855–860. [CrossRef]

16. Fabian, M.R.; Sonenberg, N.; Filipowicz, W. Regulation of mRNA translation and stability by microRNAs. *Annu. Rev. Biochem.* **2010**, *79*, 351–379. [CrossRef] [PubMed]

17. Chen, C.Y.A.; Shyu, A. Bin Mechanisms of deadenylation-dependent decay. *Wiley Interdiscip. Rev. RNA* **2011**, *2*, 167–183. [CrossRef] [PubMed]

18. Lytle, J.R.; Yario, T.A.; Steitz, J.A. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 9667–9672. [CrossRef] [PubMed]

19. Forman, J.J.; Legesse-Miller, A.; Coller, H.A. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 14879–14884. [CrossRef]

20. Friedman, R.C.; Farh, K.K.H.; Burge, C.B.; Bartel, D.P. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* **2009**, *19*, 92–105. [CrossRef]

21. Liu, B.; Li, J.; Cairns, M.J. Identifying miRNAs, targets and functions. *Brief. Bioinform.* **2015**, *16*, 834–838. [CrossRef] [PubMed]

22. El-Daly, S.M.; Abba, M.L.; Patil, N.; Allgayer, H. MiRs-134 and-370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling. *Carcinogenesis* **2012**, *33*, 1629–1638. [CrossRef] [PubMed]

23. Swierczynski, S.; Klieser, E.; Illig, R.; Alinger-Scharinger, B.; Kiesslich, T.; Neureiter, D. Histone deacetylation meets miRNA: Therapeutic implications in hematologic malignancies. *Oncotarget* **2015**, *6*, 6421–6426. [CrossRef] [PubMed]

24. Grossi, I.; Salvi, A.; Abeni, E.; Marchina, E.; De Petri, G. Biological Function of MicroRNA193a-3p in Health and Disease. *Int. J. Genom.* **2017**, *2017*. [CrossRef]

25. Nishioka, C.; Ikezoe, T.; Yang, J.; Nobumoto, A.; Tsuda, M.; Yokoyama, A. Downregulation of miR-217 correlates with resistance of ph+ leukemia cells to ABL tyrosine kinase inhibitors. *Cancer Sci.* **2014**, *105*, 297–307. [CrossRef]
40. Park, N.J.; Zhou, H.; Elashoff, D.; Henson, B.S.; Kastratovic, D.A.; Abemayor, E.; Wong, D.T. Salivary microRNA: Discovery, characterization, and clinical utility for oral cancer detection. *Clin. Cancer Res.* 2009, 15, 5473–5477. [CrossRef] [PubMed]

41. Webster, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The microRNA spectrum in 12 body fluids. *Clin. Chem.* 2010, 56, 1733–1741. [CrossRef]

42. Fabris, L.; Calin, G.A. Circulating free xeno-microRNAs—The new kids on the block. *Mol. Oncol.* 2016, 10, 503–508. [CrossRef]

43. Allegra, A.; Alongi, A.; Campo, S.; Penna, G.; Petrushar, A.; Gerace, D.; Musolino, C. Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer (Review). *Int. J. Oncol.* 2012, 41, 1897–1912. [CrossRef]

44. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc. Natl. Acad. Sci. USA* 2008, 105, 10515–10518. [CrossRef] [PubMed]

45. Bayraktar, R.; Van Roosbroeck, K.; Calin, G.A. Cell-to-cell communication: microRNAs as hormones. *Mol. Oncol.* 2017, 11, 1673–1686. [CrossRef] [PubMed]

46. Bullock, M.D.; Silva, A.M.; Kanlikilicer-Unalidi, P.; Filant, J.; Rashed, M.H.; Sood, A.K.; Lopez-Berestein, G.; Calin, G.A. Exosomonal non-coding RNAs: Diagnostic, prognostic and therapeutic applications in cancer. *Non Coding RNA* 2015, 1, 53–68. [CrossRef]

47. Ohyashiki, K.; Umezu, T.; Yoshizawa, S.I.; Ito, Y.; Ohyashiki, M.; Kawashima, H.; Tanaka, M.; Kuroda, M.; Ohyashiki, J.H. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin’s lymphoma. *PloS ONE* 2011, 6, e16408. [CrossRef] [PubMed]

48. Paggetti, J.; Haderk, F.; Seiffert, M.; Janji, B.; Distler, U.; Ammerlaan, W.; Kim, Y.J.; Adam, J.; Lichter, P.; Solary, E.; et al. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. *Blood* 2015, 126, 1106–1117. [CrossRef] [PubMed]

49. Yeh, Y.Y.; Ozer, H.G.; Lehman, A.M.; Maddocks, K.; Yu, L.; Johnson, A.J.; Byrd, J.C. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. *Blood* 2015, 125, 3297–3305. [CrossRef]

50. Ferrajoli, A.; Shanafelt, T.D.; Ivan, C.; Shimizu, M.; Rabe, K.G.; Nouraee, N.; Ikuo, M.; Ghosh, A.K.; Lerner, S.; Rassenti, L.Z.; et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. *Blood* 2013, 122, 1891–1899. [CrossRef] [PubMed]

51. Casabonne, D.; Benavente, Y.; Seiffert, J.; Costas, L.; Armesto, M.; Arestin, M.; Besson, C.; Hosnijeh, F.S.; Duell, E.J.; Weiderpass, E.; et al. Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study. *Int. J. Cancer* 2020, 147, 1315–1324. [CrossRef] [PubMed]

52. Farahani, M.; Rubbi, C.; Liu, L.; Slupsry, J.R.; Kalakonda, N. CLL exosomes modulate the transcriptome and behaviour of recipient stromal cells and are selectively enriched in MIR-202-3p. *PloS ONE* 2015, 10, e0141429. [CrossRef] [PubMed]

53. Liu, J.; Cheng, Q.; Li, X.; Liu, J.; Ye, Q.; Chen, Y.; Yan, S. Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a. *Stem Cells Int.* 2017, 2017, 9012152. [CrossRef]

54. Moloudizargari, M.; Abdollahi, M.; Asghari, M.H.; Zimta, A.A.; Neagoe, I.B.; Nabavi, S.M. The emerging role of exosomes in multiple myeloma. *Blood* 2019, 38. [CrossRef] [PubMed]

55. Roccaro, A.M.; Sacco, A.; Maiso, P.; Azab, A.K.; Tai, Y.T.; Reagan, M.; Azab, F.; Flores, L.M.; Campigotto, F.; Weller, E.; et al. BM mesenchymal stem cell-derived exosomes facilitate multiple myeloma progression. *J. Clin. Invest.* 2013, 123, 1542–1555. [CrossRef]

56. Manier, S.; Liu, C.J.; Avet-Loiseau, H.; Park, J.; Shi, J.; Campigotto, F.; Salem, K.Z.; Huynh, D.; Glavey, S.V.; Rivotto, B.; et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. *Blood* 2017, 129, 2429–2436. [CrossRef]

57. Zhang, Z.-Y.; Li, Y.-C.; Geng, C.-Y.; Zhou, H.-X.; Gao, W.; Chen, W.-M. Serum exosomal microRNAs as novel biomarkers for multiple myeloma. *Hematol. Oncol.* 2019, 37, 409–417. [CrossRef]

58. Zhang, L.; Pan, L.; Xiang, B.; Zhu, H.; Wu, Y.; Chen, M.; Guan, P.; Zou, X.; Valencia, C.A.; Dong, B.; et al. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. *OncoTarget* 2016, 7, 30876–30891. [CrossRef]

59. Tanaka, M.; Oikawa, K.; Takashashi, M.; Kudo, M.; Ohyashiki, J.; Ohyashiki, K.; Kuroda, M. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. *Plos ONE* 2009, 4, e5532. [CrossRef]

60. Ohyashiki, J.H.; Umezu, T.; Kobayashi, C.; Hamamura, R.S.; Tanaka, M.; Kuroda, M.; Ohyashiki, K. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: In vivo assessment of cell to plasma ratio of miR-92a. *BMC Res. Notes* 2010, 3, 97–103. [CrossRef] [PubMed]

61. Caivano, A.; La Rocca, F.; Simeon, V.; Girasole, M.; Dinarello, S.; Laurenzana, I.; De Stradis, A.; De Luca, L.; Trino, S.; Traficante, A.; et al. MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies—A short report. *Cell. Oncol.* 2017, 40, 97–103. [CrossRef]

62. Zhi, F.; Cao, X.; Xie, X.; Wang, B.; Dong, W.; Gu, W.; Ling, Y.; Wang, R.; Yang, Y.; Liu, Y. Identification of Circulating MicroRNAs as Potential Biomarkers for Detecting Acute Myeloid Leukemia. *PloS ONE* 2013, 8, e56718. [CrossRef]

63. Caivano, A.; La Rocca, F.; Simeon, V.; Girasole, M.; Dinarello, S.; Laurenzana, I.; De Stradis, A.; De Luca, L.; Trino, S.; Traficante, A.; et al. MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies—A short report. *Cell. Oncol.* 2017, 40, 97–103. [CrossRef]

64. Wang, Z.; Zhu, B.; Huang, Z.; Chen, L.; He, Z.; Zhang, H. MicroRNAs as biomarkers in leukemia. *Stem Cell Invest.* 2014, 1, 11. [CrossRef] [PubMed]
92. Zhang, L.; Sankaran, V.G.; Lodish, H.F. MicroRNAs in erythroid and megakaryocytic differentiation and megakaryocyte-erythroid progenitor lineage commitment. *Leukemia* 2012, 26, 2310–2316. [CrossRef] [PubMed]

93. Georgantas, R.W.; Hildreth, R.; Morisot, S.; Alder, J.; Liu, C.G.; Heimfeld, S.; Calin, G.A.; Croce, C.M.; Civin, C.I. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control. *Proc. Natl. Acad. Sci. USA* 2007, 104, 2750–2755. [CrossRef]

94. Musilova, K.; Mraz, M. MicroRNAs in B-cell lymphomas: How a complex biology gets more complex. *Leukemia* 2015, 29, 1004–1017. [CrossRef]

95. Chen, C.Z.; Li, L.; Lodish, H.F.; Bartel, D.P. MicroRNAs Modulate Hematopoietic Lineage Differentiation. *Science* 2004, 303, 83–86. [CrossRef] [PubMed]

96. Benetatos, L.; Vartholomatos, G. Deregulated microRNAs in multiple myeloma. *Cancer* 2012, 118, 878–887. [CrossRef]

97. Ward, B.P.; Tsongalis, G.J.; Kaur, P. MicroRNAs in chronic lymphocytic leukemia. *Exp. Mol. Pathol.* 2011, 90, 173–178. [CrossRef]

98. Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; et al. Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc. Natl. Acad. Sci. USA* 2002, 99, 15524–15529. [CrossRef]

99. Zhang, L.; Zhou, L.; Shi, M.; Kuang, Y.; Fang, L. Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression. *Oncol. Lett.* 2018, 15, 1287–1296. [CrossRef]

100. Bhattacharya, R.; Nicolson, M.; Arvizio, R.; Wang, E.; Cortez, A.; Rossi, S.; Calin, G.A.; Mukherjee, P. MiR-15a and MiR-16 control Bmi-1 expression in ovarian carcinoma. *Cancer Res.* 2009, 69, 9090–9095. [CrossRef]

101. Xu, F.; Zhang, X.; Lei, Y.; Liu, X.; Liu, Z.; Tong, T.; Wang, W. Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma. *J. Cell. Biochem.* 2010, 111, 727–734. [CrossRef]

102. Linsley, P.S.; Schelter, J.; Burchard, J.; Kibukawa, M.; Martin, M.M.; Bartz, S.R.; Johnson, J.M.; Cummins, J.M.; Raymond, C.K.; Dai, H.; et al. Transcripts Targeted by the MicroRNA-16 Family Cooperatively Regulate Cell Cycle Progression. *Mol. Cell. Biol.* 2007, 27, 2240–2252. [CrossRef]

103. Liu, Q.; Fu, H.; Sun, F.; Zhang, H.; Tie, Y.; Zhu, J.; Xing, R.; Sun, Z.; Zheng, X. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. *Nucleic Acids Res.* 2008, 36, 5391–5404. [CrossRef]

104. Cimmino, A.; Calin, G.A.; Fabbri, M.; Iorio, M.V.; Ferracin, M.; Shimizu, M.; Wojciech, S.E.; Aqelain, R.I.; Zupo, S.; Dono, M.; et al. miR-15 and miR-16 induce apoptosis by targeting multiple cell cycle genes. *Proc. Natl. Acad. Sci. USA* 2008, 105, 13944–13949. [CrossRef]

105. Mi, S.; Lu, J.; Sun, M.; Li, Z.; Zhang, H.; Neilly, M.B.; Wang, Y.; Qian, Z.; Jin, J.; Zhang, Y.; et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. *Proc. Natl. Acad. Sci. USA* 2007, 104, 19971–19976. [CrossRef] [PubMed]

106. Wang, Y.; Li, Z.; He, C.; Wang, D.; Yuan, X.; Chen, J.; Jin, J. MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. *Blood Cells Mol. Dis.* 2010, 44, 191–197. [CrossRef] [PubMed]

107. Eis, P.S.; Tam, W.; Sun, L.; Chadburn, A.; Li, Z.; Gomez, M.F.; Lund, E.; Dahlberg, J.E. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. *Proc. Natl. Acad. Sci. USA* 2005, 102, 3627–3632. [CrossRef] [PubMed]

108. Narayan, N.; Morenos, L.; Phipson, B.; Willis, S.N.; Brumatti, G.; Eggers, S.; Lalaoui, N.; Brown, L.M.; Kosasih, H.J.; Bartolo, R.C.; et al. Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukemia. *Leukemia* 2017, 31, 808–820. [CrossRef] [PubMed]

109. Arber, D.A.; Orai, A.; Hasserjian, R.; Thiele, J.; Borowitz, M.J.; Le Beau, M.M.; Bloomfield, C.D.; Cazzola, M.; Vardiman, J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016, 127, 2391–2405. [CrossRef] [PubMed]

110. Dixon-McViter, A.; East, P.; Mein, C.A.; Cazer, J.B.; Molloy, G.; Chaplin, T.; Lister, T.A.; Young, B.D.; Debernardi, S. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. *PloS ONE* 2008, 3. [CrossRef]

111. Jongen-Lavrencic, M.; Sun, S.M.; Dijkstra, M.K.; Valk, P.J.M.; Löwenberg, B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. *Blood* 2008, 111, 5078–5085. [CrossRef] [PubMed]

112. Li, Z.; Lu, J.; Sun, M.; Mi, S.; Zhang, H.; Luo, R.T.; Chen, P.; Wang, Y.; Yan, M.; Qian, Z.; et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. *Proc. Natl. Acad. Sci. USA* 2008, 105, 15335–1540. [CrossRef] [PubMed]

113. Shell, S.; Park, S.M.; Radjabi, A.R.; Schickel, R.; Kistner, E.O.; Jewell, D.A.; Feig, C.; Lengyel, E.; Peter, M.E. Let-7 expression defines two differentiation stages of cancer. *Proc. Natl. Acad. Sci. USA* 2007, 104, 11400–11405. [CrossRef]

114. Garzon, R.; Garofalo, M.; Martelli, M.P.; Bresieewitz, R.; Wang, L.; Fernandez-Cymering, C.; Volinia, S.; Liu, C.G.; Schnittger, S.; Haerlach, T.; et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. *Proc. Natl. Acad. Sci. USA* 2008, 105, 3945–3950. [CrossRef]

115. Alcalay, M.; Tiacci, E.; Bergomas, R.; Bigerna, B.; Venturini, E.; Minardi, S.P.; Meani, N.; Diverio, D.; Bernard, L.; Tizzoni, L.; et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. *Blood* 2005, 106, 899–902. [CrossRef]

116. Russ, A.C.; Sander, S.; Lück, S.C.; Lang, K.M.; Bauer, M.; Rücker, F.G.; Kestler, H.A.; Schlenk, R.F.; Döhner, H.; Holzmann, K.; et al. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA—Target gene interactions in acute myeloid leukemia. *Haematologica* 2011, 96, 1783–1791. [CrossRef]

117. Wong, P.; Iwasaki, M.; Somerville, T.C.P.; Ficara, F.; Carico, C.; Arnold, C.; Chen, C.Z.; Cleary, M.L. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. *Cancer Res.* 2010, 70, 3833–3842. [CrossRef]
118. Handschuh, L.; Lonetti, A. Not only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies. J. Oncol. 2019, 2019, 7239206. [CrossRef]

119. Mendler, J.H.; Maharry, K.; Radmacher, M.D.; Mrózek, K.; Becker, H.; Metzeler, K.H.; Schwind, S.; Whitman, S.P.; Khalife, J.; Kohlschmidt, J.; et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J. Clin. Oncol. 2012, 30, 3109–3118. [CrossRef] [PubMed]

120. Marucci, G.; Radmacher, M.D.; Maharry, K.; Mrózek, K.; Ruppert, A.S.; Paschka, P.; Vukosavljevic, T.; Whitman, S.P.; Baldus, C.D.; Langer, C.; et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 2008, 358, 1919–1928. [CrossRef] [PubMed]

121. Kotani, A.; Ha, D.; Schotte, D.; Den Boer, M.L.; Armstrong, S.A.; Lodish, H.F. A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle 2010, 9, 1037–1042. [CrossRef]

122. Gutierrez-Camino, A.; Garcia-Obregon, S.; Lopez-Lopez, E.; Astigarraga, I.; Garcia-Orad, A. MiRNA deregulation in childhood acute lymphoblastic leukemia: A systematic review. Epigenomics 2019, 12, 69–80. [CrossRef]

123. Szczepanek, J. Role of microRNA dysregulation in childhood acute leukemias: Diagnostics, monitoring and therapeutics: A comprehensive review. World J. Clin. Oncol. 2020, 11, 348–369. [CrossRef]

124. Yang, Y.L.; Yen, C.T.; Pai, C.H.; Chen, H.Y.; Yu, S.L.; Lin, C.Y.; Hu, C.Y.; Jou, S.T.; Lin, D.T.; Lin, S.R.; et al. A double negative loop comprising ETV6/RUNX1 and MIR181A1 contributes to differentiation block in t(12;21)-positive acute lymphoblastic leukemia. PLoS ONE 2015, 10. [CrossRef] [PubMed]

125. Gafni, N.; Binder, V.; Zaliova, M.; Linka, Y.; Morrow, M.; Novosel, A.; Edry, L.; Hertzberg, L.; Shomron, N.; Williams, O.; et al. Hsa-mir-125b-2 is highly expressed in childhood ETVD/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia 2010, 24, 89–96. [CrossRef] [PubMed]

126. Grobelaar, C.; Ford, A.M. The Role of MicroRNA in Paediatric Acute Lymphoblastic Leukemia: Challenges for Diagnosis and Therapy. J. Oncol. 2019, 2019, 8941471. [CrossRef] [PubMed]

127. Organista-Nava, J.; Gómez-Gómez, Y.; Illades-Aguiar, B.; Leyva-Vázquez, M.A. Regulation of the miRNA expression by TEL/AML1, BCR/ABL, MLL/AF4 and TCF3/PBX1 oncoproteins in acute lymphoblastic leukemia (Review). Oncol. Rep. 2016, 36, 1226–1232. [CrossRef] [PubMed]

128. Yamada, N.; Noguchi, S.; Kumazaki, M.; Shinohara, H.; Miki, K.; Naoe, T.; Akao, Y. Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukemia Jurkat cells by modulating expression of Fas-associated protein with death domain (FADD). Biochim. Biophys. Acta Mol. Cell Res. 2014, 1843, 590–602. [CrossRef]

129. Yan, Z.X.; Zheng, Z.; Xue, W.; Zhao, M.Z.; Fei, X.C.; Wu, L.L.; Huang, L.M.; Leboeuf, C.; Janin, A.; Wang, L.; et al. MicroRNA181A is overexpressed in T-cell leukemia/lymphoma and related to chemoresistance. Biomed Res. Int. 2015, 2015, 197241. [CrossRef] [PubMed]

130. Oliveira, L.H.; Schiaivito, J.L.; Fraguas, M.S.; Lucena-Araujo, A.R.; Haddad, R.; Araujo, A.G.; Dalmazoo, L.F.; Rego, E.M.; Covas, D.T.; Zago, M.A.; et al. Potential roles of microRNA-29a in the cellular pathophysiology of T-cell acute lymphoblastic leukemia. Cancer Sci. 2015, 106, 1264–1277. [CrossRef]

131. Zaliova, M.; Stuchly, J.; Winkowska, L.; Musilova, A.; Fiser, K.; Slamova, M.; Starkova, J.; Vaskova, M.; Hrusak, O.; Sramkova, L.; et al. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort. Haematologica 2019. [CrossRef]

132. Schotte, D.; Pieters, R.; Den Boer, M.L. MicroRNAs in acute leukemia: From biological players to clinical contributors. Leukemia 2012, 26, 1–12. [CrossRef]

133. Li, Y.; Yuan, Y.; Tao, K.; Wang, X.; Xiao, Q.; Huang, Z.; Zhong, L.; Cao, W.; Wen, J.; Feng, W. Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate. PLoS ONE 2013, 8, e61858. [CrossRef]

134. Fulci, V.; Colombo, T.; Chiarietti, S.; Messina, M.; Citarella, F.; Tavolaro, S.; Guarini, A.; Foà, R.; Macino, G. Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of microRNA and mRNA expression profiles. Genes Chromosom. Cancer 2009, 48, 1069–1082. [CrossRef]

135. Mavrakis, K.J.; Wolfe, A.L.; Oricchio, E.; Palomero, T.; De Keersmaecker, K.; McJunkin, K.; Zuber, J.; James, T.; Chang, K.; Khan, A.A.; et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukemia. Nat. Cell Biol. 2010, 12, 372–379. [CrossRef]

136. Huang, W.; Wang, W.T.; Fang, K.; Chen, Z.H.; Sun, Y.M.; Han, C.; Sun, L.Y.; Luo, X.Q.; Chen, Y.Q. MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47. Mol. Cancer 2018, 17, 12. [CrossRef] [PubMed]

137. La Starza, R.; Barba, G.; Demeyer, S.; Perini, V.; Di Giacomo, D.; Gianfelici, V.; Schwab, C.; Matteucci, C.; Vicente, C.; Cools, J.; et al. Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. Haematologica 2016, 101, 951–958. [CrossRef] [PubMed]

138. Li, X.J.; Luo, X.Q.; Han, B.W.; Duan, F.T.; Wei, P.P.; Chen, Y.Q. MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBPS51 and IGF1R/mTOR signalling pathways. Br. J. Cancer 2013, 109, 2189–2198. [CrossRef]
139. Avigad, S.; Verly, I.R.; Lebel, A.; Kordi, O.; Shichrur, K.; Ohali, A.; Hameiri-Grossman, M.; Kaspers, G.J.; Cloos, J.; Fronkova, E.; et al. miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia. Genes Chromosom. Cancer. 2016, 55, 328–339. [CrossRef] [PubMed]

140. Mahdloo, T.; Sahami, P.; Ramezani, R.; Jafarinia, M.; Goudarzi, H.; Babashah, S. Up-regulation of miR-155 potentiates CD34+ CML stem/progenitor cells to escape from the growth-inhibitory effects of TGF-β1 and BMP signaling. EXCLI J. 2021, 20, 748–763. [CrossRef]

141. Silvestri, G.; Trotta, R.; Stramucci, L.; Ellis, J.J.; Harb, J.G.; Neviani, P.; Wang, S.; Eisfeld, A.-K.; Walker, C.J.; Zhang, B.; et al. Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. Blood Cancer Discov. 2020, 1, 48–67. [CrossRef]

142. Zhang, B.; Nguyen, L.X.T.; Li, L.; Zhao, D.; Kumar, B.; Wu, H.; Lin, A.; Pellicano, F.; Hopcroft, L.; Su, Y.L.; et al. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat. Med. 2018, 24, 450–462. [CrossRef]

143. Ruiz, M.S.; Sanchez, M.B.; Bonecker, S.; Furtado, C.; Koide, D.; Yankilevich, P.; Cranco, S.; del Custidiano, M.R.; Freitas, J.; Moiraghi, B.; et al. miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: A potential new pharmacogenomic tool. Front. Pharmacol. 2021, 11, 2231. [CrossRef]

144. Yeh, C.H.; Moles, R.; Nicot, C. Clinical significance of microRNAs in chronic and acute human leukemia. Mol. Cancer 2016, 15. [CrossRef]

145. Wienholds, E.; Plasterk, R.H.A. MicroRNA function in animal development. FEBS Lett. 2005, 579, 5911–5922. [CrossRef] [PubMed]

146. Albano, F.; Anelli, L.; Zagaria, A.; Liso, V.; Rocchi, M.; Specchia, G. MIRN199B downregulation in chronic myeloid leukemia is associated with deletions on der(9). Br. J. Haematol. 2009, 144, 271–273. [CrossRef] [PubMed]

147. Albano, F.; Anelli, L.; Zagaria, A.; Coccaro, N.; Casiere, P.; Rossi, A.R.; Vicari, L.; Liso, V.; Rocchi, M.; Specchia, G. Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Mol. Cancer 2010, 9, 1–17. [CrossRef] [PubMed]

148. Salati, S.; Salvestrini, V.; Carretta, C.; Genovese, E.; Rontauroli, S.; Zini, R.; Rossi, C.; Ruberti, S.; Bianchi, E.; Barbieri, G.; et al. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget 2017, 8, 49451–49469. [CrossRef] [PubMed]

149. Zagaria, A.; Anelli, L.; Albano, F.; Vicari, L.; Schiavone, E.M.; Annunziata, M.; Pane, F.; Liso, V.; Rocchi, M.; Specchia, G. Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia. Cancer Genet. Cytogenet. 2006, 167, 97–102. [CrossRef]

150. Albano, F.; Anelli, L.; Zagaria, A.; Coccaro, N.; D’Addabbo, P.; Liso, V.; Rocchi, M.; Specchia, G. Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia. Oncogene 2010, 29, 2509–2516. [CrossRef]

151. San José-Enríquez, E.; Román-Gómez, J.; Jiménez-Velasco, A.; Garate, L.; Martin, V.; Cordeu, L.; Vilas-Zornoza, A.; Rodríguez-Otero, P.; José Calasanz, M.; Prößper, F.; et al. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol. Cancer 2009, 8, 69. [CrossRef]

152. Hershkovitz-Rokah, O.; Modai, S.; Pasmanik-Chor, M.; Toren, A.; Schomron, N.; Raanani, P.; Shlipberg, O.; Granot, G. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer Genet. Cytogenet. 2016, 20, 579–605. [CrossRef] [PubMed]
160. Fabbri, M.; Bottoni, A.; Shimizu, M.; Spizzo, R.; Nicoloso, M.S.; Rossi, S.; Barbarotto, E.; Cimmino, A.; Adair, B.; Wojcik, S.E.; et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA J. Am. Med. Assoc. 2011, 305, 59–67. [CrossRef]

161. Balatti, V.; Acunzo, M.; Pekary, Y.; Croce, C.M. Novel mechanisms of regulation of miRNAs in CLL. Trends Cancer 2016, 2, 134–143. [CrossRef]

162. Lavrov, A.V.; Chelysheva, E.Y.; Adiligereeva, E.P.; Shukhov, O.A.; Smirnikhina, S.A.; Kocergin-Nikitsky, K.S.; Yakushina, V.D.; Tsaur, G.A.; Mordanov, S.V.; Turkina, A.G.; et al. Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients. BMC Med. Genom. 2019, 12. [CrossRef] [PubMed]

163. Ohyashiki, K.; Umezu, T.; Katagiri, S.; Kobayashi, C.; Azuma, K.; Tauchi, T.; Okabe, S.; Fukuoka, Y.; Ohyashiki, J.H. Downregulation of plasma miR-215 in chronic myeloid leukemia patients with successful discontinuation of imatinib. Int. J. Mol. Sci. 2016, 17, 570. [CrossRef]

164. Marton, S.; Garcia, M.R.; Robello, C.; Persson, H.; Trajtenberg, F.; Pritsch, O.; Rovira, C.; Naya, H.; Dighiero, G.; Cayota, A. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 2008, 22, 330–338. [CrossRef]

165. Tili, E.; Michaille, J.J.; Luo, Z.; Volinia, S.; Rassenti, L.Z.; Kipps, T.J.; Croce, C.M. The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood 2012, 120, 2631–2638. [CrossRef]

166. Psathas, J.N.; Doonan, P.J.; Raman, P.; Freedman, B.D.; Minn, A.J.; Thomas-Tikhonenko, A. Lymphoid neoplasia: The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: A novel lymphomagenic feed-forward loop. Blood 2013, 122, 4220–4229. [CrossRef]

167. Xiao, C.; Calado, D.P.; Galler, G.; Thai, T.H.; Patterson, H.C.; Wang, J.; Rajewsky, N.; Bender, T.P.; Rajewsky, K. MiR-150 Controls B Cell Differentiation by Targeting the Transcription Factor c-Myc. Cell 2007, 131, 146–159. [CrossRef]

168. Zhou, B.; Wang, S.; Mayr, C.; Bartel, D.P.; Lodish, H.F. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc. Natl. Acad. Sci. USA 2007, 104, 7080–7085. [CrossRef] [PubMed]

169. Hu, H.; Wang, B.; Borde, M.; Nardone, J.; Maika, S.; Allred, L.; Tucker, P.W.; Rao, A. Foxp1 is an essential transcriptional regulator of B cell development. Nat. Immunol. 2006, 7, 819–826. [CrossRef] [PubMed]

170. Mraz, M.; Chen, L.; Rassenti, L.Z.; Ghia, E.M.; Li, H.; Jepsen, K.; Smith, E.N.; Messer, K.; Frazer, K.A.; Kipps, T.J. MiR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood 2014, 124, 84–94. [CrossRef]

171. Vargova, K.; Pesta, M.; Obtrilikova, P.; Dusilkova, N.; Minarik, L.; Vargova, J.; Berkova, A.; Zemanova, Z.; Michalova, K.; Spacek, M.; et al. MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. Blood Cancer J. 2017, 7, e585. [CrossRef]

172. Balatti, V.; Pekary, Y.; Croce, C.M. Role of microRNA in chronic lymphocytic leukemia onset and progression. J. Hematol. Oncol. 2015, 8, 12. [CrossRef] [PubMed]

173. Pekarsky, Y.; Santanum, U.; Cimmino, A.; Palamarchuk, A.; Efanov, A.; Maximov, V.; Volinia, S.; Alder, H.; Liu, C.G.; Rassenti, L.; et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006, 66, 11590–11593. [CrossRef]

174. Palamarchuk, A.; Yan, P.S.; Zanesi, N.; Wang, L.; Rodrigues, B.; Murphy, M.; Balatti, V.; Bottoni, A.; Nazaryan, N.; Alder, H.; et al. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc. Natl. Acad. Sci. USA 2012, 109, 2555–2560. [CrossRef] [PubMed]

175. Sharma, S.; Pavlasova, G.; Seda, V.; Cerna, K.; Vojackova, E.; Filip, D.; Ondrisova, L.; Sandova, V.; Kostalova, L.; Zeni, P.F.; et al. miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: An Axis Affected by BCR inhibitors. Blood 2020, 137. [CrossRef]

176. Saleh, L.M.; Wang, W.; Herman, S.M.; Saba, N.S.; Anastas, V.; Barber, E.; Corrigan-Cummins, M.; Farooqui, M.; Sun, C.; Sarasua, S.M.; et al. Btruthinb downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. Leukemia 2017, 31, 340–349. [CrossRef] [PubMed]

177. De Leeuw, D.C.; Denkers, F.; Olthof, M.C.; Ruiten, A.P.; Pουwels, W.; Schuurhuis, G.J.; Ossenkoppele, G.J.; Smit, L. Attenuation of microRNA-126 expression that drives CD4+CD38+—stem/progenitor cells in acute myeloid leukemia. Cancer Res. 2014, 74, 2094–2105. [CrossRef]

178. Wang, H.; Jiang, Y.; Peng, H.; Chen, Y.; Zhu, P.; Huang, Y. Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. Adv. Drug Deliv. Rev. 2015, 81, 142–160. [CrossRef]

179. Meister, G.; Landthaler, M.; Dorsett, Y.; Tuschl, T. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 2004, 10, 544–550. [CrossRef]

180. Huang, X.; Schwind, S.; Yu, B.; Santhanham, R.; Wang, H.; Hoellerbauer, P.; Mims, A.; Klisovic, R.; Walker, A.R.; Chan, K.K.; et al. Targeted delivery of miRNA-29b by transfer-conjugated anionic lipopolypeptide nanoparticles: A novel therapeutic strategy in acute myeloid leukemia. Clin. Cancer Res. 2013, 19, 2355–2367. [CrossRef]

181. Dei Martino, M.T.; Leone, E.; Amoedo, N.; Foresta, U.; Lionetti, M.; Pitari, M.R.; Gallo Cantafio, M.E.; Gullà, A.; Conforti, F.; Morelli, E.; et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence. Clin. Cancer Res. 2012, 18, 6260–6270. [CrossRef]
182. Salerno, E.; Scaglione, B.J.; Coffman, F.D.; Brown, B.D.; Baccarini, A.; Fernandes, H.; Marti, G.; Raveche, E.S. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. *Mol. Cancer Ther.* 2009, 8, 2684–2692. [CrossRef] [PubMed]

183. Kasar, S.; Salerno, E.; Yuan, Y.; Underbayev, C.; Vollenweider, D.; Laurindo, M.F.; Fernandes, H.; Bonci, D.; Addario, A.; Mazzella, F.; et al. Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. *Genes Immun.* 2012, 13, 109–119. [CrossRef]  

184. Zhu, D.X.; Zhu, W.; Fang, C.; Fan, L.; Zou, Z.J.; Wang, Y.H.; Liu, P.; Hong, M.; Miao, K.R.; Liu, P.; et al. MiR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. *Carcinogenesis* 2012, 33, 1294–1301. [CrossRef] [PubMed]

185. Dereani, S.; Macor, P.; D’Agaro, T.; Mezzaroba, N.; Dal-Bo, M.; Capolla, S.; Zucchetto, A.; Tissino, E.; Del Poeta, G.; Zorzet, S.; et al. Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. *J. Hematol. Oncol.* 2014, 7. [CrossRef] [PubMed]

186. Chiang, C.L.; Goswami, S.; Frissora, F.W.; Xie, Z.; Yan, P.S.; Bundschuh, R.; Walker, L.A.; Huang, X.; Mani, R.; Mo, X.M.; et al. ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. *Blood* 2019, 134, 432–444. [CrossRef]

187. D’Abundo, L.; Callegari, E.; Bresin, A.; Chillemi, A.; Elamin, B.K.; Guerriero, P.; Huang, X.; Saccenti, E.; Hussein, E.M.A.A.; Casciano, F.; et al. Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. *Oncogene* 2017, 36, 6617–6626. [CrossRef]

188. Shaham, L.; Binder, V.; Gefen, N.; Borkhardt, A.; Izraeli, S. MiR-125 in normal and malignant hematopoiesis. *Leukemia* 2012, 26, 2011–2018. [CrossRef]

189. Svoronos, A.A.; Engelman, D.M.; Slack, F.J. OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. *Cancer Res.* 2016, 76, 3666–3670. [CrossRef]